Remternetug

Remternetug (LY3372993) is Eli Lilly's next-generation anti-amyloid antibody, designed to clear a chemically-modified form of amyloid that accumulates specifically in brain plaques, delivered as a subcutaneous injection instead of the hours-long IV infusions required for current therapies [1][2]. It hits the same target as Lilly's already-approved Kisunla (donanemab), making this a franchise extension rather than a new mechanism [3]. Two programs are running in parallel: TRAILRUNNER-ALZ 1, a 1,667-patient Phase 3 in early symptomatic AD that has completed enrollment [2], and a Phase 2/3 arm within the DIAN-TU-002 platform testing whether the drug can prevent disease in carriers of dominantly inherited AD mutations that guarantee early-onset disease [4]. The commercial logic is straightforward: convert Kisunla's infusion-clinic burden into an at-home injection, capture patients who cannot access infusion centers, and ride the same disease-modifying claim that earned donanemab approval in 2024 [5]. Against a Lilly 2025 revenue base of ~$65B [6], remternetug is not a moonshot — it is franchise defense in a class where Kisunla's launch has been slower than expected due to logistics and payer friction.

TRAILRUNNER-ALZ 1 (NCT05463731) completed enrollment at 1,667 participants with early symptomatic Alzheimer's, sponsored by Lilly [2]. The primary endpoint is percentage achieving amyloid plaque clearance on PET — the same surrogate Lilly used to win donanemab approval — rather than cognitive decline directly [2][5]. The DIAN-TU-002 arm (NCT06647498), sponsored by Washington University, is recruiting 280 carriers of dominantly inherited AD mutations across the platform; the remternetug arm uses centiloid change on PiB-PET (centiloid = a standardized scale for amyloid plaque burden; PiB-PET is the brain-scan technology used to measure it) as its Stage 1 biomarker primary endpoint [4][7]. Lilly has disclosed a PK bridging study in Chinese participants (specific NCT registration pending independent confirmation), likely intended to support global registration. Critically, Lilly has not publicly published detailed Phase 1/2 subcutaneous PK bridging data comparing subQ remternetug to IV donanemab brain exposure; if such data remains unpublished at TRAILRUNNER-ALZ 1 readout, it will be the first question from FDA and payers. Remternetug has no FDA breakthrough or fast-track designation publicly disclosed, which is unusual for a high-profile anti-amyloid program — likely because Lilly already has Kisunla approved in this class, weakening the unmet-need argument FDA uses to grant breakthrough status to follow-on assets [5]. Expect a topline readout from TRAILRUNNER-ALZ 1 in 2026-H2, with a BLA filing plausible thereafter depending on the depth of clearance data and the ARIA safety profile [6]. The DIAN-TU prevention readout is estimated 2028-2030 based on platform enrollment pace, and runs on a different commercial clock.

Amyloid beta is a small protein fragment that aggregates into plaques between brain cells. In Alzheimer's, these plaques accumulate for a decade or more before symptoms appear, and the dominant hypothesis is that they trigger downstream damage to neurons [9]. Remternetug targets a specific chemical modification — pyroglutamate-modified amyloid beta, abbreviated N3pG-Aβ — that gets added to amyloid beta after it is already stuck in plaques [1][3]. In plain terms: the drug ignores floating, soluble amyloid and goes straight for the deposited gunk, marking it for clearance by microglia (the brain's resident cleanup cells). This is the same epitope donanemab (Kisunla) hits, which is the entire reason this asset exists — Lilly knows the mechanism works because donanemab slowed clinical decline by roughly 35% in low/medium-tau patients in TRAILBLAZER-ALZ 2 and got approved in July 2024 [3][5]. So the question with remternetug is not 'will it clear plaques' — donanemab proved that — but 'can a subcutaneous formulation deliver enough antibody to match the IV depth of clearance.' The biology validation is as strong as it gets for any AD target: post-mortem confirmation of plaque removal, PET imaging confirming dose-response, and a regulatory precedent [1][9]. Lecanemab (Leqembi, Eisai/Biogen) hits a different amyloid conformation and also got approved, further de-risking the class [10].

TRAILRUNNER-ALZ 1 is a 1,667-patient placebo-controlled Phase 3 randomizing early symptomatic Alzheimer's patients (MCI or mild dementia, amyloid-positive on PET) [2]. The primary endpoint is percentage achieving amyloid plaque clearance on PET defined relative to placebo — a surrogate, not a cognitive endpoint. This is the same regulatory playbook Lilly ran with donanemab, where amyloid clearance carried weight because the class has independent cognitive evidence [3][5]. The trial is well-powered for the surrogate, but FDA may ask for a cognitive co-endpoint or post-approval confirmatory data given the class is no longer first-in-disease. Comparator is placebo, which is appropriate because there is no standard subcutaneous anti-amyloid option to benchmark against. Enrollment completed in 2025 per ClinicalTrials.gov [2]. The DIAN-TU-002 arm is a smaller platform trial in roughly 280 mutation carriers across dominantly inherited AD (DIAD) families — a population guaranteed to develop AD, which makes prevention signals interpretable in shorter timeframes than in sporadic AD [4][7]. Its primary biomarker endpoint is centiloid change on PiB-PET. The main design concern is that the surrogate-endpoint strategy worked once (donanemab), but FDA tolerance for amyloid-only data may tighten as the class matures and clinical-benefit debates continue [1]. The trial does not appear to stratify by APOE4 status as a primary analysis layer — relevant because APOE4 homozygotes have disproportionately high rates of ARIA, the class-defining safety signal [10].

Our model estimates a 9% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase and the sponsor's strong record of getting drugs approved; it is held back by heavier-than-usual blinding and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: low at the surrogate level — amyloid clearance is essentially mechanism-confirmation, and donanemab already showed this antibody class clears plaques [3][5]. The harder question is whether subcutaneous PK delivers enough antibody to brain to match IV donanemab's depth of clearance. Shallower clearance weakens both regulatory and payer arguments. Safety risk: ARIA (amyloid-related imaging abnormalities) is the class signature — brain swelling (ARIA-E) and microhemorrhage (ARIA-H) seen on MRI, occasionally symptomatic, rarely fatal [1][10]. For reference, TRAILBLAZER-ALZ 2 reported ARIA-E in ~24% and ARIA-H in ~31% of donanemab-treated patients; these are the baseline comparators for any subQ safety readout [3]. APOE4 homozygotes are the highest-risk subgroup. Donanemab's label carries warnings; lecanemab's open-label extension reported ARIA-related deaths in patients on concurrent anticoagulants, and anticoagulant co-use is now a label warning for the class [10]. Subcutaneous dosing could either soften or worsen the ARIA profile depending on Cmax — unknown until the Phase 3 safety database publishes. Execution risk: enrollment is done; the bigger execution question is the BLA package. FDA's 2024 advisory committee for donanemab was contentious despite approval. A second franchise asset entering with surrogate-only data could face tougher scrutiny [5]. Commercial risk is the largest near-term issue. Kisunla's launch has been slower than Leqembi due to infusion-clinic logistics, prior-auth friction, and modest cognitive benefit relative to cost (~$32,000/year list) [6]. If remternetug launches at similar pricing with similar effect size but home injection, it cannibalizes Kisunla rather than expanding the market — Lilly is fine with that, but absolute revenue lift may disappoint. Payers are pushing back hard on the entire anti-amyloid class; CMS coverage is restrictive. Subcutaneous convenience helps adherence but does not fix payer math.

Worth watching, but the signal is narrower than the Phase 3 readout headline suggests. The relevant question is not 'does remternetug clear amyloid' — donanemab already proved the mechanism works — but 'does the subcutaneous formulation match IV depth of clearance, and at what ARIA cost?' If both metrics match Kisunla, remternetug becomes the default anti-amyloid asset for Lilly's franchise and Kisunla effectively retires within 2-3 years [5][6]. Specific data points to watch: (1) percent of patients achieving complete plaque clearance at the timepoint comparable to donanemab's TRAILBLAZER-ALZ 2 — anything below 60% at 18 months signals the subQ route under-delivers [3], (2) ARIA-E and ARIA-H rates by APOE4 status, especially in homozygotes, benchmarked against donanemab's ~24%/31% — anything materially worse is a payer killer [3][10], and (3) any FDA signal on whether amyloid clearance alone supports approval or whether cognitive data will be required for the BLA. Check back at TRAILRUNNER-ALZ 1 topline expected 2026-H2; watch Lilly Q1/Q2 2026 earnings calls and investor day commentary for filing timing [6]. The DIAN-TU readout is estimated 2028-2030 based on platform enrollment pace and is a separate scientific story — primary prevention in genetic AD is more interesting biology but the smaller commercial bet [4]. Connection to Lilly: 2025 revenue was ~$65B per 10-K [6]; Kisunla is a small contributor relative to incretins (analyst peak sales estimates for the donanemab/remternetug franchise generally sit in the $1-3B range, dwarfed by tirzepatide), but the AD franchise matters for Lilly's positioning as a CNS player. This is franchise defense, not a moonshot.